Company: PSTV
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013256
Chunk: 28

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 28
---
 the event of a fundamental transaction, subject to certain exceptions as described in the Warrants and Prefunded Warrants, the holders of the Warrants and Prefunded Warrants shall have the option, exercisable at any time concurrently with, or within thirty days after, the consummation of a fundamental transaction, to require the Company or a successor entity to purchase the Warrants and Prefunded Warrants for cash in the amount of the Black Scholes Value (as defined in each of the Warrants and Prefunded Warrants) of the unexercised portion of the Warrants or Prefunded Warrants, provided, however, that if the fundamental transaction is not within the Company’s control, the holder of Warrants or Prefunded Warrants will only be entitled to receive the same type or form of consideration (and in the same proportion) at the Black Scholes Value of the unexercised portion of such Warrants or Prefunded Warrants that is being offered and paid to the holders of Common Stock in connection with the fundamental transaction.

Governing Law. The Prefunded Warrants and the Warrants are governed by New York law.

#### Purpose of the Warrant Stockholder Approval
In order to comply with Nasdaq Listing Rule 5635(d) and permit the holders to exercise the Warrants, the stockholders of the Company need to approve the issuance of the Warrants and the Warrant Shares issuable upon exercise of the Warrants together with the additional shares of our Common Stock that may become issuable upon adjustments provided for under the Warrants and the provisions of the Warrants indicated above. Until the Company obtains the Warrant Stockholder Approval in order to comply with Nasdaq Listing Rule 5635(d), the Warrants are not exercisable.

**Potential Adverse Effects of the Approval of the Warrant Stockholder Approval Provisions**

Following approval by the stockholders of this proposal, existing stockholders, other than the holders of the Warrants whose ownership interests would materially increase if they exercise their Warrants, will suffer significant dilution in their ownership interests upon exercise of the Warrants. Assuming the full exercise of the Series A Warrants after a reset of the exercise price to the Floor Price of $0.132, and assuming the Series B Warrants are exercised on a zero exercise price basis after a reset of the exercise price to the Floor Price of $0.132, an aggregate of 280,421,380 shares of Common Stock would become issuable upon the exercise of the Series A Warrants